Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy

Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy

Ching-Chih Hu,1,2 Cheng-Hao Weng,2,3 Liang-Che Chang,4 Chih-Lang Lin,1,2 Yen-Ting Chen,1 Ching-Fang Hu,5 Man-Chin Hua,2,6 Li-Wei Chen,1 Rong-Nan Chien2,7 1Department of Hepatogastroenterology, Chang Gung Memorial Hospital, Keelung, Taiwan; 2College of Medicine, Chang Gung University, Linkou, Taiwan...

Full description

Bibliographic Details
Main Authors:	Hu CC, Weng CH, Chang LC, Lin CL, Chen YT, Hu CF, Hua MC, Chen LW, Chien RN
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-04-01
Series:	Therapeutics and Clinical Risk Management
Subjects:	hepatocellular carcinoma chronic hepatitis C advanced fibrosis sustained virologic response pegylated interferon
Online Access:	https://www.dovepress.com/simple-score-to-predict-risk-of-hepatocellular-carcinoma-in-chronic-he-peer-reviewed-article-TCRM

Similar Items

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
by: Zheng C, et al.
Published: (2019-04-01)

Characteristics of hepatitis C treatment with pegylated interferons and ribavirin
by: Ricardo Jiménez-Méndez, et al.
Published: (2010-01-01)

Pegylated Interferons and Their Use in Clinical Practice
by: Alpay AZAP, et al.
Published: (2003-12-01)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
by: Janine Hartl, et al.
Published: (2012-07-01)

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
by: Byung Chul You, et al.
Published: (2012-09-01)

Pegylated Interferon (Alone or With Ribavirin) for Chronic Hepatitis C in Haemodialysis Population
by: Mario Espinosa, et al.
Published: (2015-05-01)

Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
by: Elson Vidal Martins Jr., et al.
Published: (2009-11-01)

Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
by: Sergio Sabbatani, et al.

Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial
by: Miguel Ángel Jiménez-Luévano, et al.
Published: (2013-03-01)

Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha
by: Andréa Marques Vieira da Silva, et al.
Published: (2021-07-01)

Autoimmune thyroid diseases in patients with chronic hepatitis C treated by pegylated interferon-alpha and ribavirin: A prospective study
by: Ružić Maja, et al.
Published: (2017-01-01)

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection
by: Fabien Zoulim, et al.
Published: (2018-01-01)

Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients
by: Chen Z, et al.
Published: (2017-08-01)

Pityriasis Rosea Associated with Pegylated Interferon Alfa and Ribavirin Treatment in a Patient with Chronic Hepatitis C
by: Rahmet Güner, et al.
Published: (2013-06-01)

The interleukin 28B gene polymorphism, rs8099917, in patients with chronic hepatitis C and response to the treatment with pegylated interferon and ribavirin
by: Hamid Kalantari, et al.
Published: (2019-01-01)

The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients
by: Nishikawa Hiroki, et al.
Published: (2012-03-01)

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
by: Marisa Boff Costa, et al.
Published: (2018-01-01)

Effect of Pegylated Interferon on Non-Responders and Relapsers with Interferon
by: Hisham O. Akbar, et al.
Published: (2002-04-01)

Pulmonary hazards of chronic hepatitis C virus infection treatment with Pegylated interferon and ribavirin vs. untreated patients
by: Sanaa Elhelaly, et al.
Published: (2013-04-01)

Efficacy of combined antiviral therapy with pegylated interferon α-2a and ribavirin for chronic hepatitis C infection in intravenous drug users
by: Ružić Maja, et al.
Published: (2010-01-01)

Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT
by: Jaber Al-Ali, et al.
Published: (2012-03-01)

Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b
by: Jovanović-Ćupić Snežana, et al.
Published: (2014-01-01)

Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort
by: Ta-Wei Liu, et al.
Published: (2018-01-01)

Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
by: Malgorzata Inglot, et al.
Published: (2013-03-01)

Evaluation of the Results of Patients Treated By Pegylated Interferon Alpha Therapy
by: Çiğdem PAPİLA, et al.
Published: (2015-09-01)

Antiviral/immunomodulatory combination therapy: Pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection
by: Delić Dragan, et al.
Published: (2012-01-01)

Analysis of hepatitis C virus (HCV) RNA load in platelets of HCV-monoinfected patients receiving antiviral therapy
by: Márcia Paschoal do Espírito-Santo, et al.
Published: (2013-05-01)

Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon – Ribavirin in daily practice
by: Ezequiel Ridruejo, MD., et al.
Published: (2010-01-01)

Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?
by: Giovanni Faria Silva, et al.

Can pegylated interferon improve the outcome of polycythemia vera patients?
by: Elena Crisà, et al.
Published: (2017-01-01)

Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study
by: S K Agarwal, et al.
Published: (2016-01-01)

Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C
by: Stephen E. Livingston, et al.
Published: (2016-03-01)

Cost comparison of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine
by: Mandrik Olena, et al.
Published: (2015-01-01)

Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin
by: M.H.P. Pavan, et al.

Response predictors to treatment with pegylated interferon in chronic hepatitis B
by: Paulo Roberto Abrão Ferreira, et al.

Psoriasis induced by Interferon alfa-2a and ribavirin in a patient followed for hepatitis C
by: N. Amraoui, et al.
Published: (2015-07-01)

Protein kinase expression as a predictive factor for interferon response in chronic hepatitis C patients
by: Amal A. Mohamed, et al.
Published: (2014-01-01)

EFFICACY AND SAFETY OF THE COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON ALFA-2A IN PATIENTS WITH CHRONIC HEPATITIS C: THE RESULTS OF TWO MULTICENTER, PROSPECTIVE, OPEN, NON-COMPARATIVE CLINICAL TRIALS
by: K. V. Zhdanov, et al.
Published: (2018-01-01)

Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01)

Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C
by: Jong Wook Choi, et al.
Published: (2016-03-01)